Codex DNA, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2021
August 10, 2021 at 04:15 pm EDT
Share
Codex DNA, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2021. For the quarter, total revenue was $2,852,000 against $1,617,000 a year ago. Loss from operations was $7,572,000 against $3,296,000 a year ago. Net loss and comprehensive loss was $9,201,000 against $4,082,000 a year ago. Net loss per share - basic and diluted was $1.06 against $0.82 a year ago.
For six months, total revenue was $5,179,000 against $3,004,000 a year ago. Loss from operations was $13,836,000 against $6,891,000 a year ago. Net loss and comprehensive loss was $16,643,000 against $7,962,000 a year ago. Net loss per share - basic and diluted was $2.39 against $1.59 a year ago.
Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.
TELESIS BIO, INC. 
